Evotec AG (NASDAQ:EVO) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Evotec has a consensus “Hold” rating from five covering brokerages: two rate it a buy, two a hold and one a sell. The average 12-month price target is $3.00.
• Analysts have recently become more cautious, with multiple downgrades and price-target cuts; HC Wainwright lowered its target to $4.00 while TD Cowen set a $2.00 target.
• EVO opened at $1.80, matching its 52-week low, versus a 52-week high of $4.27. Institutional investors own 5.81% of the company, while several hedge funds recently increased their positions.

Shares of Evotec AG (NASDAQ:EVO - Get Free Report) have received a consensus recommendation of "Hold" from the five research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $3.00.

Several research firms recently weighed in on EVO. Wall Street Zen downgraded Evotec from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Weiss Ratings cut Evotec from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 25th. Berenberg Bank downgraded Evotec from a "buy" rating to a "hold" rating in a research note on Thursday, July 16th. HC Wainwright decreased their price objective on Evotec from $7.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, July 15th. Finally, TD Cowen cut Evotec from a "buy" rating to a "hold" rating and set a $2.00 price objective on the stock. in a research report on Wednesday, July 15th.

Hedge Funds Weigh In On Evotec

Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Evotec by 25.7% in the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company's stock worth $5,536,000 after purchasing an additional 367,545 shares in the last quarter. WCM Investment Management LLC lifted its stake in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company's stock valued at $1,480,000 after buying an additional 67,917 shares in the last quarter. ABC Arbitrage SA lifted its stake in shares of Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company's stock valued at $1,707,000 after buying an additional 422,230 shares in the last quarter. Optiver Holding B.V. boosted its holdings in Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company's stock worth $709,000 after buying an additional 242,973 shares during the period. Finally, Jane Street Group LLC bought a new position in Evotec in the 4th quarter worth $565,000. Hedge funds and other institutional investors own 5.81% of the company's stock.

Evotec Stock Performance

Shares of EVO stock opened at $1.80 on Wednesday. Evotec has a 1 year low of $1.80 and a 1 year high of $4.27. The firm has a fifty day moving average price of $2.20 and a 200-day moving average price of $2.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.33 and a quick ratio of 2.21.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source